Abceutics, Inc., a startup preclinical-stage biopharmaceutical company that was spun out of the laboratory of University at Buffalo researcher Joseph P. Balthasar, PhD, has been acquired by the global biopharmaceutical company Merck, known as MSD outside the U.S. and Canada. Merck acquired Abceutics for a potential consideration of up to $208 million, including contingent milestone payments based upon the progress of candidates under the agreement.
Read the full article: Abceutics, Inc., a Startup at UB, Acquired by Biopharma Company Merck //
Source: https://www.buffalo.edu/news/releases/2024/04/Abceutics-acquired-by-Merck.html